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Abstract 
Objective: To evaluate the taxonomic composition of the gut microbiome in gout patients with and without tophi 
formation, and predict bacterial functions that might have an impact on urate metabolism.
Methods: Hypervariable V3–V4 regions of the bacterial 16S rRNA gene from fecal samples of gout patients with 
and without tophi (n = 33 and n = 25, respectively) were sequenced and compared to fecal samples from 53 healthy 
controls. We explored predictive functional profiles using bioinformatics in order to identify differences in taxonomy 
and metabolic pathways.
Results: We identified a microbiome characterized by the lowest richness and a higher abundance of Phascolarc-
tobacterium, Bacteroides, Akkermansia, and Ruminococcus_gnavus_group genera in patients with gout without tophi 
when compared to controls. The Proteobacteria phylum and the Escherichia-Shigella genus were more abundant 
in patients with tophaceous gout than in controls. Fold change analysis detected nine genera enriched in healthy 
controls compared to gout groups (Bifidobacterium, Butyricicoccus, Oscillobacter, Ruminococcaceae_UCG_010, Lach-
nospiraceae_ND2007_group, Haemophilus, Ruminococcus_1, Clostridium_sensu_stricto_1, and Ruminococcaceae_
UGC_013). We found that the core microbiota of both gout groups shared Bacteroides caccae, Bacteroides stercoris ATCC 
43183, and Bacteroides coprocola DSM 17136. These bacteria might perform functions linked to one‑carbon metabo‑
lism, nucleotide binding, amino acid biosynthesis, and purine biosynthesis. Finally, we observed differences in key 
bacterial enzymes involved in urate synthesis, degradation, and elimination.
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Introduction
Gout, the most common form of inflammatory arthri-
tis is the result of chronic hyperuricemia and the sub-
sequent monosodium urate (MSU) crystal formation 
and deposition in articular cartilage and other joint and 
extra-articular tissues, which triggers an inflammatory 
response (Dalbeth et  al. 2019; Narang et  al. 2019). The 
clinical presentation includes frequent acute flares and 
chronic MSU crystal deposition, named tophus (Dalbeth 
et al. 2007). Chronic hyperuricemia is the result of envi-
ronmental factors and a genetic background for urate 
production, as well as renal and intestinal excretion (Hn 
et  al. 2019; Bobulescu and Moe 2012; Xu et  al. 2016). 
Although evolutionary and adaptive processes in humans 
have restrained uricase production, responsible for urate 
degradation into allantoin (Alvarez-Lario and Macarron-
Vicente 2010; Ramazzina et  al. 2006), certain bacteria 
residing in the gut can metabolize one-third of the daily 
urate load produced endogenously and the exogenous 
urate from dietary purines (Sorensen and Levinson 1975; 
Maiuolo et al. 2016). Shao et al. found that the signatures 
of fecal microbiome and metabolome in gout patients 
can be characterized by disorders of metabolites involved 
in urate excretion and shifts in amino acids directly 
responsible of purine nucleoside biosynthesis. They also 
identified an enrichment of opportunistic pathogens and 
a decreased α diversity (Shao et al. 2017). Another study 
revealed gut dysbiosis in gout patients and demonstrated 
that Bacteroides were common and abundant in their 
gut microbiomes compared to healthy individuals (Guo 
et al. 2015). Lim et al. showed that Bacteroides possessed 
an enrichment of the enzyme 5-hydroxysourate hydro-
lase, which plays a crucial role in gut uricolysis (Lim et al. 
2014). To date, no study has addressed the characteriza-
tion and differentiation of the gut microbiome of gout 
patients with at least one subcutaneous tophus (detect-
able by physical examination) (Bursill et  al. 2019, and 
without tophi, let alone in a western population. In this 
study, we present a robust description of the gut bacterial 
microbiome of Mexican gout patients and compare it in 
two different disease states of gout, in order to test the 
hypothesis that patients with gout and with tophaceous 
gout have changes in the structure and functional profile 
linked to uric acid synthesis and degradation pathways of 
their intestinal microbiota compared to healthy subjects.
Materials and methods
Study subjects and patients involvement
We included 58 patients with a diagnosis of gout (2015 
ACR/EULAR) (Neogi et  al. 2015): 33 had gout and at 
least one subcutaneous tophi), 25 had gout without 
subcutaneous tophi. Additionally, 53 healthy controls 
were recruited. Gout patients were consecutive patients 
attending their regular visit at one of two hospitals (Hos-
pital General de México “Eduardo Liceaga” (HGM) and 
Instituto Nacional de Rehabilitación “Luis Guillermo 
Ibarra Ibarra” (INRLGII)). Healthy controls were blood 
donors from the INRLGII blood bank. All subjects agreed 
to participate and signed an informed consent. Trained 
research staff interviewed and clinically examined all par-
ticipants. Individuals with diagnosis of diabetes, chronic 
renal failure, other rheumatic disease including other 
crystalline arthropathy (different than MSU crystals), 
Cushing syndrome, and chronic gastrointestinal diseases 
were excluded from this study. Additionally, patients 
receiving antibiotics, or antiparasitic therapy, or who 
had diarrhea in the last three months were not included 
in the study. Blood and stool samples were obtained fol-
lowing the protocol and instructions for sample collec-
tion and transport. Participants answered a previously 
validated semi-quantitative food frequency questionnaire 
about diet and medications (data will be published in a 
separate article). This study followed all statements of 
the Helsinki Declaration and was approved by the Ethics 
and Research Committee of the INRLGII (INR28/15) and 
HGM (DI/18/404-A/03/004).
Anthropometric and biochemical assessment
A blood sample was taken by venipuncture from all par-
ticipants within a fasting period of 8–12 h. Glucose, cho-
lesterol, triglycerides, and urate levels were measured by 
spectrophotometry in a microplate absorbance reader 
(iMArk, Bio-Rad, CA, EUA) and following the manufac-
turer’s instructions (DiaSys, Holzheim Germany). The 
body mass index (BMI) was calculated using standard 
anthropometric parameters.
Sample collection, DNA extraction and sequencing
All participants were ask to provide a fresh stool sample 
(the first bowel movement of the day). Previously to the 
collection of the sample participants were instructed by 
Conclusion: Our findings revealed that taxonomic variations in the gut microbiome of gout patients with and with‑
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trained personnel for the correct way of collecting the 
sample and provided with the material needed. All sam-
ples were transport at 4 °C and stored within the first 2 h 
at − 80  °C. DNA was extracted from each sample using 
the QIAamp DNA stool kit (QIAGEN, Hilden, Germany) 
according to the manufacturer’s protocol. Sequenc-
ing libraries were built following a two-step polymerase 
chain reaction (PCR) protocol suggested by Illumina 
(Illumina, San Diego, CA, USA). The presence of ampli-
cons (~ 560-bp) was confirmed by gel electrophoresis on 
a 1.5% agarose gel. Each sample was then purified with 
QIAquick PCR purification kit (QIAGEN, Hilden, Ger-
many) and quantified by using Agilent 4200 Tape Station 
System (Agilent, Santa Clara, CA, United States). The 
final libraries were pooled at 4 pM with the addition of 
10% PhiX into the final pool and subsequently sequenced 
using the Illumina Miseq platform (Illumina, San Diego, 
CA, USA), following the manufacturer’s specifications.
Bioinformatics analysis
All raw sequence reads were filtered under a strict qual-
ity preprocessing protocol to remove sequences with 
Phred quality score < Q30 using fastp tool v0.20.0 (Chen 
et al. 2016). After filtering, 91% of the sequencing reads 
reached Q30 (99.9% base call accuracy) for controls 
and cases sequences. Consequently, paired reads were 
merged using PEAR v0.9.10 (Zhang et  al. 2014) with a 
threshold of 20 bp minimum overlap and imported into 
QIIME2, version 2019.4 (Bolyen et al. 2019). Afterwards, 
chimeras were removed, and sequences were denoised 
with -p-trim-length script, truncating reads at a position 
250 using Deblur algorithm (Amir et  al. 2017). Overall, 
we obtained 3,444,321 clean and filtered sequences with 
a mean count of 31,599 reads per sample.
Taxonomy assignment was performed against the 
SILVA v132 ribosomal reference database (Quast et  al. 
2012), clustered at 99% sequence similarity. The result-
ing amplicon sequence variants (ASVs) abundance table, 
metadata, and taxonomy data were imported into phy-
loseq (McMurdie and Holmes 2013) and analyzed with R 
Studio version 3.5.2 (http:// www. rstud io. com).
The ASV table was rarefied to adjust the sampling 
depth among samples to the one with the lowest reads. 
Alpha diversity metrics for richness (observed species, 
Chao1, ACE) and diversity (Shannon and Simpson) were 
estimated and compared using phyloseq. For multiple 
comparison adjustment we calculated the false discov-
ery rate (FDR) using the Hommel method. In addition, 
we analyzed richness and diversity indices removing 
BMI ≥ 30  kg/m2 (five samples from the gout group and 
three from the tophaceous gout group).
Relative log expression (RLE) normalization method 
to test for differential abundance of ASVs was performed 
in DESeq2 (Love et al. 2014). To visualize the variations 
in bacterial community composition according to stud-
ied groups’ metadata, we calculated beta-diversity with 
a principal coordinate analysis (PCoA) of Bray–Cur-
tis dissimilarity based on ASV composition. We used a 
permutational multivariate analysis of variance (PER-
MANOVA) to test differences between groups, and 
p < 0.05 was taken as statistical significance. For the 
taxonomic composition analysis and visualization, stats 
and ggplot2 R packages were used. The Kruskall-Wallis 
test was first applied to compare ASVs among groups; 
only if the Kruskall-Wallis test showed a p < 0.05 was the 
Wilcoxon sum-rank test performed to compare pairs of 
groups. We generated boxplots of the ASV relative abun-
dances using amp_boxplot function (within the ampvis2 
package v.2.5.9) (Andersen et al. 2018). Fold changes were 
also calculated by dividing the median values of group 
abundances for significant results obtained from the Wil-
coxon analysis. Besides, a Linear Discriminant Analysis 
(LDA) was performed with MASS package in R to test 
whether the taxa abundances detected in the non-para-
metric tests and fold changes were able to discriminate 
between groups. Based on an abundance ratio parameter 
of 0.8, and an ASVs removal with an abundance < 0.01% 
of the total read count proposed by Astudillo-García 
(Astudillo-García et al. 2017), we generated a Venn dia-
gram and Krona plots to show unique and common ASVs 
among groups.
We used an in silico approach to infer bacterial pro-
tein–protein interaction (PPI) networks, using the 
STRING-DB version 11.0 (https:// string- db. org), and to 
predict the role that bacterial species shared between 
gout groups might play in purine metabolism. Statis-
tical significance was considered with p-values under 
0.05. The resulting ASV table was used to predict KEGG 
Ortholog (KO) functional profiles of bacterial communi-
ties from 16S rRNA data using the Tax4Fun2 R package 
(https:// sourc eforge. net/ proje cts/ tax4f un2/).
We applied a two-sided Welch’s t-test in STAMP (Sta-
tistical Analysis of Metagenomic Profiles) (Parks and 
Beiko 2013) to establish statistical differences and to 
determine possible enriched bacterial functions among 
groups.
Results
Differentially abundant taxa and alpha diversity 
among study groups
Additional file 1: Table S1 illustrates the anthropometric 
and biochemical features of patients and controls; BMI, 
glucose, and triglycerides were higher in gout patients 
and tophaceous gout patients than in healthy controls.
The following richness indices were significantly 
increased in healthy controls compared to gout patients: 
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Chao1 (p = 0.049), Observed species (p = 0.041), and 
ACE (p = 0.044) (Fig.  1). After multiple comparison 
adjustment, the difference seen in Chao1, Observed spe-
cies and ACE between control group and gout patients 
remained significant (p = 0.049). Rarefaction curves for 
each sample are shown in (Additional file  2: Fig. S1). 
Nonetheless, no statistical difference was found in the 
Shannon and Simpson diversity indices. Tophaceous 
gout patients exhibited no statistical variation in any of 
the α-diversity parameters. Alpha diversity analysis with-
out patients with BMI ≥ 30  kg/m2 provided substantial 
confirmation of the findings obtained in Fig.  1 (Addi-
tional file  3: Fig. S2 A). Moreover, beta-diversity was 
non-significantly different between the study groups 
(Additional file 3: Fig. S2B). Sequences were assigned to 
5349 amplicon sequence variants (ASVs) at ≥ 99% simi-
larity and clustered into 5 phyla, 9 classes, 11 orders, 21 
families, and 63 genera. At the phylum level, Proteobac-
teria was significantly more abundant in tophaceous gout 
patients than in healthy controls (p < 0.05) (Fig.  2). The 
relative abundance of the 50 most abundant genera is 
shown in Additional file 4: Fig. S3. Pairwise comparison 
Fig. 1 Alpha‑diversity plots of bacterial communities in the microbiome of study groups. Variations for richness (Observed, Chao1, ACE) and 
diversity (Shannon and Simpson) indexes between both gout groups and healthy controls. *Significant difference after multiple comparison 
adjustment
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Fig. 2 Relative abundance of ASVs at the phylum level. Stacked bar plots represent the relative abundance at the phylum level using SILVA 132 
database. Boxplots showing comparative distribution of Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria and Verrucomicrobia in controls (red 
bars), in gout group (green bars) and in the tophaceous gout group (blue bars). Boxes denote the interquartile range (IQR) between the first and 
third quartiles, and the line inside represents the median (2nd quartile). Whiskers show the lowest and the highest values
Fig. 3 a Fold change of the relative abundances of bacterial genera showing significant differences between both gout groups and healthy 
controls. Purple color (positive fold change) and orange color (negative fold change) indicate an increase or a decrease of the bacterial genera 
within each group, respectively. b Linear discriminant analysis (LDA) plot of genera abundances data derived from non‑parametrical statistical 
analysis shows the significance of genera combinations in differentiating the three study groups
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based on a fold change cut-off ≥  ± 1.5 revealed twenty 
differentially abundant taxa at the genus level among 
groups. Of these, nine genera were more abundant in the 
control group, eight were overrepresented in gout group, 
and five were enriched in the tophaceous group (Fig. 3a). 
Lineal Discriminant Analysis showed that Rumino-
coccus_1, Clostridium_sensu_stricto_1, Oscillibacter, 
Butyricicoccus, Ruminococcaceae_UCG_010, Bifidobac-
terium, Lachnospiraceae_ND3007_group, Haemophilus, 
and Ruminococcaceae_UGC_013 were the detected gen-
era in the non-parametric tests and fold changes that can 
discriminate between the control group from the two 
gout groups. Moreover, Phascolarctobacterium, Bac-
teroides, Lachnospira, Erysipelotrichaceae_UCG_003, 
Ruminococcaceae_UGC_013, Roseburia, Akkermansia, 
and Ruminococcus_gnavus_group, have the ability to dis-
criminate between gout group, from controls and topha-
ceous gout group. While, Escherichia-Shigella, Sarcina, 
Rikenellaceae_RC9, Lachnospiraceae_NK4B4, and Lach-
nospiraceae_ND3007 were the combination of genera 
that best discriminate tophaceous gout from the other 
groups (Fig. 3b).
Defining a core microbiota of gout
Based on a 0.01 relative abundance cut-off, we observed 
that both gout groups (gout patients and tophaceous gout 
patients) shared 130 overlapping ASVs (Fig.  4a). Of the 
total ASVs detected, 1302 represented an exclusive com-
position in gout patients, whereas 1381 ASVs belonged 
to tophaceous gout patients, and 1974 were unique to 
healthy controls; interestingly, 286 ASVs were common 
to all samples. Krona charts were used to represent the 
relative taxonomic contribution (ASV percentages) from 
all samples (Additional file 5: Fig. S4).
The most abundantly shared ASVs between both 
gout groups at the genus level were Faecalibacterium, 
Ruminococcaceae_NK4A214_group, Ruminococcaceae_
UCG-005, Ruminococcaceae_UCG-14, Veillonella, 
Phascolarctobacterium. Interestingly, Prevotella_9 and 
Bacteroides (both from the Bacteroidales family) were the 
most representative genera of this phylum among these 
two groups. The most representative Proteobacteria 
genus was Escherichia-Shigella (34%) (Fig. 4b). We found 
a core of three most abundant ASVs within the genus 
Bacteroides that included Bacteroides caccae, Bacteroides 
stercoris ATCC 43,183, and Bacteroides coprocola DSM 
Fig. 4 a Venn diagram showing the number of shared and unique core ASVs among the three study groups. The core microbiota in the gout 
groups is exhibited in the overlap of the green and blue circles. b Krona chart representing the taxonomic composition and relative abundance of 
the most abundant ASVs found in the gout groups
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17,136 (Additional file 5: Fig. S4A). We identified 174 and 
192 ASVs shared among healthy controls/gout patients 
(Additional file  5: Fig. S4B) and healthy controls/topha-
ceous gout patients, respectively (Additional file  5: Fig. 
S4C).
Functional prediction of bacteria in the core microbiota 
of gout patients is linked to the synthesis of intermediate 
metabolites for purine formation
We explored a functional protein association network 
focusing on three species of bacteria (Bacteroides cac-
cae, Bacteroides stercoris ATCC 43183, and Bacteroides 
coproccola DSM 17136) shared between both gout 
groups (Fig.  5a–c). The STRING analysis of Bacteroides 
caccae revealed a significant enrichment (p = 0.0001) of 
protein–protein interaction (PPI) among eleven proteins. 
Five of these functional pairs were proteins involved in 
purine metabolism (pbux (xanthine permease), guaB 
(inosine-5′ monophosphate dehydrogenase), purL (phos-
phoribosylformylglycinamidine synthase), xpt (xanthine 
phosphoribosyltransferase)). This enrichment indicates 
that proteins are partially biologically connected and 
actively involved in purine metabolism (FDR = 0.0003), 
GMP biosynthesis (FDR = 0.0009), and glutaminase 
activity (glutamine amidotransferase) (FDR = 0.004) 
(Fig. 5a).
For Bacteroides stercoris ATCC 43183, the pro-
teins detected were significantly enriched in four 
pathways: purine biosynthesis, one-carbon metabo-
lism, nucleotide-binding, and amino-acid biosynthe-
sis, with a FDR of 2.55e−18, 0.002, 0.016, and 0.043, 
respectively. The proteins detected were: bifunctional 
purine biosynthesis protein (PurH), AICAR transfor-
mylase/IMP cyclohydrolase (PurH), serine hydroxym-
ethyltransferase (glyA), adenylosuccinate synthetase 
(purA), phosphoribosylamine-glycine ligase (purD), 
phosphoribosylglycinamide formyltransferase (purN), 
5-phospho-ribosyl-N-formylglycinamide (purL), phos-
phoribosylaminoimidazole-succinocarboxamide (SAI-
Fig. 5 Protein–protein interaction analysis predicted by STRING. Nodes are colored based on their specific role: purine biosynthesis (red), 
one‑carbon metabolism (blue), nucleotide‑binding (yellow), ligases (pink), and amino acid biosynthesis (green). Proteins involved in multiple 
functions are filled with various colors. Thicker lines define the most robust associations. a Bacteroides caccae showed significant enrichment of 
proteins strongly involved in purine metabolism. b Bacteroides stercoris ATCC 43183, displayed functional categories included purine biosynthesis, 
one‑carbon metabolism, nucleotide‑binding, and amino‑acid biosynthesis. c For Bacteroides coproccola DSM 17136 and Bacteroides stercoris ATCC 
43183 we identified protein–protein interaction in enzymes involved in one‑carbon metabolism, purine biosynthesis, as well as methyltransferases, 
transferases, and ligases
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CAR) synthase (purC), and inosine-5′-monophosphate 
dehydrogenase (guaB) (Fig. 5b).
A shared PPI network for three targeted proteins that 
are also involved in purine biosynthesis (FDR = 0.002), 
and three proteins that participates in one carbon 
metabolism (FDR = 1.76e−05) was detected between 
Bacteroides coprocola DSM 17136 and Bacteroides ster-
coris ATCC 43183. Moreover, B. coprocola DSM 17136 
had an enrichment in protein–protein interaction that 
included three methyltransferases (glyA, gcvT, and thyA) 
Fig. 6 Stacked column bar graph representing the predicted metabolic characteristics that differentiate between a tophaceous gout patients vs. 
healthy controls, b gout patients vs. healthy controls, and c tophaceous gout patients vs. gout patients. Differences were considered significant at 
p‑value < 0.05 using Welch’s t‑test
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(FDR = 0.001), six transferases (purN, purH, glytA, gcvT, 
EDU99278.1, and fmt) (FDR = 4.60e−05) and two ligases 
(fhs and folC) (FDR = 0.030) (Fig. 5c).
Variations in key bacterial enzymes among study groups
We observed 47 KEGG functional orthologues related to 
the oxidative metabolism of purines, metabolic pathways 
for purine biosynthesis, vitamin B12 transport, and urate 
excretion that were significantly different between groups 
(Fig. 6a–c).
Vitamin B12 (permease protein and substrate binding 
protein), nucleoside permease, glycine cleavage system 
transcriptional repressor, several xanthine dehydrogenase 
iron-sulfur-binding subunits, xanthine and nucleoside 
phosphorylases, methionine transaminase, oxidoreduc-
tases, transferases, hydrolases were much higher in the 
fecal microbiome of tophaceous gout patients compared 
to healthy controls. Urea carboxylase and urease acces-
sory protein were more enriched in healthy controls 
(Fig. 6a).
The KEGG pathway analysis also detected significant 
differences in microbiome functions between healthy 
controls and the gout patients. Glycine dehydrogenase 
subunit was the only enzyme enriched in gout patients 
compared to healthy controls. Two urease subunits were 
more abundant in the microbiome of healthy controls 
compared to gout patients (Fig. 6b).
The abundance of glycine reductase complex compo-
nent B subunits alpha, beta and gamma was significantly 
higher in gout patients than tophaceous gout patients, 
whereas purine nucleosidase abundance was higher in 
tophaceous gout patients (Fig. 6c).
KEGG enzyme and orthology identifier for bacterial 
proteins that were significantly different among study 
groups are in Additional file 6: Table S2.
Discussion
Despite accounting for only one-third of total urate 
excretion, the impact of intestinal urate excretion in gout 
disease is scarcely understood. Recent investigations have 
shown a recurrent pattern associated with alterations 
in bacterial species richness, and in their crucial func-
tions in the intestine. Our study found taxonomic vari-
ations and shifts among gout patients, tophaceous gout 
patients, and healthy controls regarding bacterial func-
tions involved in urate metabolism.
Some studies suggest that low bacterial richness in the 
gut microbiome is associated with chronic diseases and 
a more pronounced inflammatory phenotype (Chatelier 
et al. 2013). Notably, our analysis showed a lower species 
richness in gout patients than in healthy controls. Our 
results are consistent with previous reports that found 
lower bacterial diversity in Chinese gout patients, sug-
gesting intestinal dysbiosis (Shao et al. 2017).
We found a significantly higher abundance of 
butyrate-producing bacteria (Butyricicoccus and Oscil-
libacter) in healthy controls. This is the first time that 
the genus Butyricicoccus is reported as significantly 
overrepresented in healthy controls compared to gout 
patients. Healthy controls also exhibited an enrich-
ment of previously reported beneficial genera, such 
as Bifidobacterium, Clostridium_sensu_stricto_1, and 
Ruminococcus_1. Interestingly, the coexistence of 
butyrate-producing and Bifidobacterium genera may 
contribute to the maintenance of the intestinal bar-
rier, as well as the immunomodulatory and anti-inflam-
matory processes (Riviere et  al. 2016; Devriese et  al. 
2017; Krumbeck et  al. 2018). Zhuang et  al. reported 
similar findings of metagenomic species enriched in 
the gut microbiome of healthy controls (Clostridium 
butyrate-producing bacteria and Bifidobacterium pseu-
docatenulatum). They also observed that Ruminococcus 
abundance was negatively associated with gout disease 
(Guo et al. 2015).
Phascolarctobacterium and Bacteroides were the most 
enriched genera in both gout groups. These genera have 
been found more abundantly in the intestinal tract of a 
hyperuricemic rat model (Liu et al. 2020). Bacteroides is a 
gut enterotype reported to promote urate conversion into 
allantoin, and hence might be involved in serum urate 
level regulation in humans (Lim et al. 2014). The Akker-
mansia genus, which we also found more abundantly in 
Gout patients than in healthy controls and tophaceous 
gout patients, was previously reported in higher abun-
dance among young patients with enthesitis-related 
arthritis (Stoll et al. 2019).
Additionally, we identified a “core microbiota” for the 
two gout groups encompassing three Bacteroides species. 
A recent study reported enrichment of Bacteroides and in 
particular Bacteroides caccae in gout patients (Shao et al. 
2017).
Yamauchi et  al. demonstrated how some bacterial 
species within the gut microbiome could release many 
metabolites and protein molecules that distinctively 
impact host purine levels (Yamauchi et  al. 2020). Given 
that enrichment of Bacteroides may be the footprint of 
gout disease, our work implied an understanding of the 
role of Bacteroides species found in the core microbiota 
of gouty patients. We identified multiple proteins that 
orchestrate de novo synthesis, salvage, and formation 
of purine intermediates with protein networks stored in 
STRING.
The fecal microbiome of male gout patients was also 
found to be enriched in certain amino acids, including 
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glycine. Reductive glycine pathway could be a critical 
metabolic route for assimilating one-carbon compounds 
(Yishai et al. 2018). One-carbon metabolism mediated by 
folate cofactor supports purine biosynthesis and amino 
acid homeostasis, including glycine, serine, and methio-
nine (Ducker and Rabinowitz 2017). Consistent with the 
reports on Chinese patients (Shao et al. 2017), our find-
ings show that both glycine dehydrogenase and glycine 
reductase were significantly higher in gout patients com-
pared to healthy controls and tophaceous gout patients. 
Moreover, enzymes involved in methionine transamina-
tion, vitamin B12 transport system, and glycine cleavage 
system were increased in tophaceous gout patients com-
pared to healthy controls. Therefore, we believe that the 
gut microbiome of gout patients not only participates in 
nucleotide salvage and de novo purine biosynthesis path-
ways, but also performs essential functions in the de novo 
synthesis of purine precursors (such as glycine), as well as 
in the synthesis of 10f-formyltetrahydrofolate.
The purine nucleosidase enzyme that we observed to 
be differentially abundant in tophaceous gout patients 
compared to gout patients is involved in the formation 
of nucleobases (Kopecna et  al. 2013). In 2006, Ogawa 
reported that a high nucleoside activity of some anaero-
bic bacteria residing in the gut of hyperuricemic rats 
helped lower the elevated serum urate levels in these 
animals. Therefore, purine nucleoside may play a specific 
role in serum urate level modulation in tophaceous gout 
patients (Ogawa 2006).
When compared to healthy controls, tophaceous gout 
patients had an enrichment of Proteobacteria, accompa-
nied by significant increases in Escherichia-Shigella, Sar-
cina, Rikenellaceae_RC9, and Lachnospiraceae_NK4B4. 
Similar results were previously reported (Xi et al. 2019), 
where a high proliferation of Proteobacteria (particularly 
Escherichia-Shigella) was found in the gut microbiota of 
animals lacking urate oxidase. Thus, the presence of these 
bacteria might play a crucial role in the development of 
gout. Additionally, it is well known that enrichment of 
Proteobacteria may represent the dysbiosis signature in 
the gut microbiota (Shin et al. 2015). We have elucidated 
the enrichment of three bacterial xanthine dehydroge-
nase isoforms with oxidoreductase activity in topha-
ceous gout patients. A previous study showed an increase 
in xanthine dehydrogenase in gout patients (Guo et  al. 
October 2015). This enzyme plays key roles in the succes-
sive oxidation of hypoxanthine to xanthine and xanthine 
to urate (Wang et al. 2016). Urate is oxidized, producing 
5-hydroxysourate, allantoin, (S)-ureidoglycine, and the 
end product of purine catabolism, glyoxylate, in order 
to yield oxalurate and glycine (Ramazzina et  al. 2010). 
This process enables gut bacteria to obtain carbon and 
nitrogen. Hualin Xi et al. revealed that bacterial lineages 
belonging to Escherichia-Shigella, which were enriched 
among tophaceous gout patients in our study, might 
contribute to purine salvage by inducing the xanthine 
dehydrogenase activity (Xi et  al. 2000). They also pro-
posed that this action may allow these bacteria to obtain 
nitrogen as a means of survival. Another important find-
ing was the enrichment of the enzymes involved in the 
final purine catabolism (5-hydroxyisourate hydrolase, 
allantoate deiminase, and (S)-ureidoglycine aminohydro-
lase) in tophaceous gout patients versus healthy controls. 
There is evidence of an adaptive response of Escherichia-
Shigella members to long-term nitrogen starvation in 
anaerobic environments, which requires allantoin deg-
radation (Switzer et  al. 2020). It is worth noting that E. 
coli can obtain four nitrogen atoms from purines, while 
it can only gain one nitrogen atom from each uracil mol-
ecule through the reductive pyrimidine catabolic path-
way (Salway 2018; Yin et al. 2019). We hypothesized that 
the increased activity of xanthine dehydrogenase and the 
enzymes of ureide synthesis in tophaceous gout patients 
is likely an adaptive process of the gut microbiome, which 
may be attributable to more than 8  years of allopurinol 
treatment. This antihyperuricemic drug inhibits urate 
production and, hence, allantoin formation by bacteria 
(Yang et al. 2012).
Finally, ureases were the most elevated enzymes in 
healthy controls compared to gout patients, suggesting 
that intestinal microbiota ureases may play a crucial role 
in the final degradation of purine and ureides in order to 
produce urea. Urea hydrolysis enables nitrogen acquisi-
tion as a valuable energy source (Kanamori et  al. 2004; 
Mora and Arioli 2014).
A remarkable limitation of our study is that 16s rRNA 
data do not allow direct inference of genes from the 
bacterial population found. Therefore, future research 
should be carried out with metagenomic shotgun 
sequencing and metatranscriptomics analysis. This 
would enable more accurate inferences about bacte-
rial structure and real gene expression to identify the 
strain-specific genomic features. Another limitation that 
is worth mentioning is that BMI was significantly differ-
ent among our study groups. In Mexico, gout tends to be 
more severe than in other countries, and obesity is fre-
quently associated with this type of inflammatory arthri-
tis, especially among subjects with a shorter duration of 
the disease (Vázquez-Mellado et  al. 2006). The patients 
included in our study showed higher BMI than control 
group, especially the group of gout patients. We consid-
ered this an intrinsic limitation given the behavior of the 
disease. Nonetheless, we think this does not affect our 
results, given that the composition of the gut microbiota 
of gout patients was found to be enriched with bacterial 
genus reported in some studies as decreased in obese 
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individuals (Bacteroides and Akkermansia) (Crovesy et al. 
2020). Furthermore, we obtained similar findings in alpha 
diversity indices with rarefaction excluding samples from 
patients with a BMI ≥ 30 kg/m2, suggesting that the lower 
diversity observed in gout patients is not due to obesity 
but to gout itself.
On the other hand, despite the differences observed in 
serum glucose levels, we avoided the inclusion of those 
individuals with fasting glucose > 126  mg/dL since it 
would indicate diabetes diagnosis according to the Amer-
ican Diabetes Association (ADA) (previously listed in 
the exclusion criteria). This strategy helped us to avoid 
including patients with both gout and type 2 diabetes 
(T2D). Nonetheless, gout is a highly complex metabolic 
disease, and the positive correlation between hyperurice-
mia and hyperglycemia has been long studied (Griffiths 
1950). Despite that the etiological mechanisms behind 
this relationship are not fully understood, hyperuricemia 
has been proven to be the first metabolic disruption to 
appear in patients not only with T2D but also in meta-
bolic syndrome (MetS) patients (Johnson 2015; Li et  al. 
2013), two of the most prevalent comorbidities of gout. 
This could be the reason for the significant difference 
we observed in glucose levels among controls and gout 
patients, and supports the notion that the results pre-
sented here reflects the truly metabolic disruption seen 
in gout patients.
Conclusions
In conclusion, our results highlight the taxonomic com-
position differences of the gut microbiota between two 
gout groups at different stages of the disease compared 
to healthy subjects. In general, we found enrichment of 
distinct functions within the microbiome of both gout 
groups related to urate metabolism, one-carbon metabo-
lism, and both amino acid and purine biosynthesis.
The gut microbiome has become an essential compo-
nent for understanding gout complexity, and its shifts 
showed in this study may provide metabolic footprints of 
gout patients and healthy individuals. Further studies are 
needed to understand how to reestablish or inhibit gut 
microbiome functions in gout patients to achieve lower 
serum urate levels.
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